PR Newswire
MISSISSAUGA, Ontario, Feb. 27, 2017
-Executive Management to Host Conference Call on March 13, 2017 at 9:00
a.m. ET-
MISSISSAUGA, Ontario, Feb. 27, 2017 /PRNewswire/
-- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) today announced that it will report its 2016 fourth quarter
and full-year financial results on Monday, March 13, 2017, before the opening of the U.S. financial
markets. Following the announcement, executive management will host a conference call and webcast at 9:00
a.m. ET on such date to discuss the financial results, recent highlights highlights and guidance for 2017 financial
results .
Audio Webcast/ Conference Call Details
Date: Monday, March 13, 2017
Time: 9:00 a.m. ET
Dial-in (U.S.): 877-407-8037
Dial-in (International): 201-689-8037
A live webcast and audio archive for the event may be accessed from the Investors section of the Aralez website at www.aralez.com. Please connect to the website prior to the start of
the presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of
the webcast will be archived on the website for two weeks.
About Aralez Pharmaceuticals Inc.
Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ and TSX: ARZ) is a global specialty pharmaceutical company focused on
delivering meaningful products to improve patients' lives while creating shareholder value by acquiring, developing and
commercializing products primarily in cardiovascular, pain and other specialty areas. Aralez's Global Headquarters is in
Mississauga, Ontario, Canada, its U.S. Headquarters is in Princeton,
NJ and the Ireland Headquarters is in Dublin, Ireland. More information about Aralez can
be found at www.aralez.com .
Aralez Pharmaceuticals US Inc. Contact
Nichol L. Ochsner
Executive Director, Investor Relations & Corporate Communications
732-754-2545
nochsner@aralez.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aralez-to-announce-fourth-quarter-and-full-year-2016-results-on-march-13-2017-300413623.html
SOURCE Aralez Pharmaceuticals Inc.
